“Psychotropic Drug Prescriptions Increase at State Prisons”
Thirty-three percent of all inmates in New Mexico are taking at least one psychotropic drug. The rate is up from 25% in 2013, according to a report by The Santa Fe New Mexican. While the prescription rate at the federal level is 10%, 30% of male inmates and 70% of female inmates in New Mexico are prescribed psychotropic drugs.
Long-Term Social Supports Needed After Onset of Psychosis
New data on the effects of social support after early onset of psychosis suggests that patients with intense social support function better than those without such help, but than once supports are removed the effects diminish.
Pennsylvania Foster Kids Prescribed Too Many Psychotropic Drugs
Amid growing criticism about the over-prescription of psychotropic medication in foster care, Pennsylvania commissioned PolicyLab to conduct an analysis of the use of psychiatric drugs among all of the state’s Medicaid-enrolled children. The report, released in June, found that the rate of psychotropic prescriptions among youth in Medicaid and foster care was higher than previously reported.
An “Epidemic of Anguish” on College Campuses?
The Chronicle of Education has called the soaring rates of anxiety and depression among college student an “Epidemic of Anguish.” PBS interviews Jennifer Ruark, the editor of the Chronicle series, and Micky Sharma, the director of counseling at Ohio State University. Ruark reports that about “1 in 4 students reporting to campus counseling centers now are already on some kind of psychotropic medication.” Sharma adds that “just because a student is crying does not mean he or she needs psychotherapy. Sometimes that’s actually the type of emotional response that I would want to see.”
Meta-Analysis Ties Gray Matter Loss to Antipsychotic Dose
Antipsychotics are currently the predominant treatment for individuals diagnosed with schizophrenia, but there is an accumulating body of research that links the use of these drugs to structural abnormalities in the brain. A recent meta-analysis suggests that gray matter loss in the brain may depend on the dose and class of the antipsychotic.
“NYS Moves to Parity in Mental Health Treatment”
New York State has investigated five large insurance companies for violating state and federal mental health parity laws by illegally denying to cover claims for behavioral health conditions and drug abuse treatment, according to a report by North County Public Radio (ncpr).
Antipsychotics Prescribed Off-Label for Challenging Behaviors
Antipsychotics are being prescribed to people who may have challenging behaviors but no mental disorder, according to new research published in this month’s issue of BMJ. “Excessive use of psychotropic drugs has individual and systemic implications,” the researchers write. “Antipsychotics, in particular, are associated with several adverse side effects that can impair quality of life and lead to deleterious health outcomes.”
“More Evidence that Antipsychotics Shrink the Brain”
New research finds that brain matter loss in patients diagnosed with schizophrenia is correlated with antipsychotic use, according to Psych Central. The analysis suggests that the continued use of antipsychotics is linked with progressive cortical gray matter loss.
“Antipsychotic Use in Youth Without Psychosis: A Double-edged Sword”
This month’s issue of JAMA Psychiatry ran an editorial commenting on recent research revealing that the majority of youth prescribed antipsychotics have not been diagnosed with a mental disorder.
“Forgiving Others Can Protect You From Depression”
A new study out of the University of Missouri examines the relationship between forgiveness and depression. Medical Daily reports, “while your therapist might tell you to forgive yourself when times get tough, it’s not always just self-forgiveness that decreases depression. Rather, forgiving others seems to have the most positive impact.”
Members of FDA Advisory Committee Offer Perspectives on Flibanserin Approval in JAMA
In the September issue of The Journal of the American Medical Association (JAMA) three FDA advisory committee members describe the convergence of factors that made the committee’s recommendation to approve flibanserin especially challenging and politically charged.
“California Moves to Stop Misuse of Psychiatric Meds in Foster Care”
On Tuesday, NPR told the story of DeAngelo Cortijo. DeAngelo became a foster kid at age 3 after his mother attempted suicide. He was “diagnosed with bipolar and anxiety disorders, attachment disorder, intermittent explosive disorder or posttraumatic stress disorder,” and was prescribed “a combination of antipsychotics, antidepressants and stimulants, and was told that taking them was his only hope of being normal.” Through equine therapy, DeAngelo was eventually able to get off all of his medication. Now, California is hoping to pass reforms that would prevent foster kids, like DeAngelo, from being “prescribed antipsychotic drugs at double to quadruple the rate of that not in foster care.”
“The Decline of Play in Preschoolers and the Rise in Sensory Issues”
“We are consistently seeing sensory, motor, and cognitive issues pop up more and more in later childhood, partly because of inadequate opportunities to move and play at an early age,” writes Angela Hanscom in The Washington Post.
From Self-Harm to Self-Empowerment: Liberation Through Words
In contemporary U.S. culture, people who intentionally hurt their bodies are called “insane.” We may starve ourselves or carve ourselves, taking to the extreme culturally-embedded norms like thinness in an effort to fight against marginalization or cope with internalized shame. But instead of obtaining the voice or place in society we yearn for, we are further ostracized.
Study 329: The Timelines
In addition to hosting the Panorama programs and The Famous Grouse history of Study 329, Study329.org has a comprehensive timeline on the origins of concerns about the SSRIs and the risk of suicide, initially with Prozac and subsequently with Paxil/Seroxat. The hope is to provide a comprehensive repository for anyone who wants to study SSRIs, RCTs, and Study 329 in particular.
CNN: Are Medications An Effective PTSD Treatment?
"CNN's Carol Costello explores Operation Tohidu, an experimental rehabilitation program to help veterans with PTSD." Operation Tohidu founder, Dr. Mary Vieten claims PTSD is not a mental illness and "there is no reason to medicate someone who has been traumatized by their war experience." When asked what percentage of soldiers returning with PTSD do not need drugs she responds, "100%."
“Janssen Accused of Withholding Data on Risperdal Side Effect in Autism”
MedPageToday reports that Janssen Pharmaceuticals omitted data from a 2003 study that connected Risperdal with serious side effects. Janssen was previously sued by the FDA for marketing Risperdal for off-label uses and settled for $2.2 billion in 2013. Earlier this year, a man with autism was awarded $2.5 million after growing breasts while on Risperdal. According to MedPage, documents from this latest case reveal missing data tables from a 2003 study “designed to ferret out potential adverse effects of long-term risperidone use.” The missing tables were related to elevated prolactin levels and side effects, including gynecomastia in men.
Parents Opposed to Pot Argues Pitt Study Neglects Increased THC
Parents Opposed to Pot, a group opposed to the legalization of marijuana, criticizes a recent University of Pittsburgh study which found no correlation between pot use and mental health. They contest the results and insist that since the long-term study began in 1987, “skunk” or high THC pot has been on the rise.
“The FDA Is Basically Approving Everything. Here’s The Data To Prove It”
Writing for Forbes, Matthew Herper documents the FDA’s increasing drug approval rates. “In 2008, BioMedTracker says the FDA approved 20 new molecular entities (NMEs) and rejected 20, for an approval rate of 50%.” So far this year, he writes, “the FDA approval rate is more like 96%.”
Harvard’s Madras Critiques University of Pittsburgh Marijuana Study
Bertha Madras, professor of psychobiology at Harvard Medical School, has printed a critique listing 20 flaws to a recent study finding no differences in physical or mental health problems between users and non-users of marijuana.
Hearing Voices Network Responds to Susan Inman HuffPo Piece
On Saturday morning, Susan Inman, writing for HuffPost Canada, published “What You’re not Hearing About the Hearing Voices Movement.” In it, she criticizes HVM for “failing to differentiate between the needs of people who actually have psychotic disorders and those who don't.” On Sunday the Bay Area Hearing Voices Network published an open letter in response, writing: “Ms. Inman has profoundly mischaracterized hearing voices networks (HVNs) and also demonstrates a troubling lack of understanding of the empirical literature on psychosis, optimal psychosocial intervention and recovery.”
“New Depression Meds Not Effective Generally, But Drug Companies Insist Otherwise: Study”
The International Business Times covers a new study showing “trials for new antidepressant medications may not be applicable to the population at large.” “The finding, published in the Mayo Clinic Proceedings, shows recent trials are less generalizable than the prior studies, as researchers excluded most depressed patients from drug company-sponsored treatment studies.”
“Post-Katrina Stress Disorder: Climate Change and Mental Health”
Writing for Truth-Out, hurricane Katrina survivor G. Maris Jones writes: “To adapt to a changing climate, survivors of these catastrophes - especially those in marginalized, low-income communities - need long-term physical and mental health services.” She adds a concurrent call to “assume our responsibility to make positive change through action on climate change.”
“Belief That Mental Illness Can Be Contagious Contributes To Isolation”
Tania Lombrozo for New Hampshire Public Radio (nhpr) asks, “could it be that some people believe psychiatric disorders can be contagious?” A new study in the Journal of Memory & Cognition says “yes,” and adds that this perception influences the way people interact with mental health category members.
Concern that Generic Antipsychotics May Lead to Rise in Off-label Prescribing to Children
Healthline reports that as five second-generation antipsychotics (SGAs) lose patent protection, Medicaid expenditures for antipsychotics are projected to be cut in half over the next five years. But some worry that the decrease in spending may lead policymakers to lift existing restrictions on antipsychotics at a time when most SGAs are prescribed to children for off-label reasons.